Literature DB >> 10734427

Estrus synchronization with lower dose of PGF2 alpha and subsequent fertility in subestrous buffalo.

K R Chohan1.   

Abstract

Two experiments were conducted to determine luteal regression, estrous response and fertility in buffalo receiving cloprostenol via 2 routes of administration. In Experiment 1, cyclic buffalo (n = 10) were assigned to 2 equal groups receiving either 500 micrograms i.m. cloprostenol (Estrumate, ICI) or 125 micrograms cloprostenol injected intravulvosubmucosal (ivsm) ipsilateral to the side of the corpus luteum (CL) on Day 11 of an induced estrous cycle. Serum progesterone (P4) concentrations were evaluated immediately before treatment and at 24, 48, 72, 96 and 120 h after PGF2 alpha administration. The decline in serum P4 concentrations was significantly different (P < 0.05) between groups up to 48 hrs after treatment. However, no significant difference (P > 0.05) was observed for the interval from treatment to the onset of estrus (94.9 +/- 10.7 vs 96.0 +/- 15.9 h) for 500 or 125 micrograms of cloprostenol groups, respectively. In Experiment 2, multiparous, lactating subestrous buffaloes (n = 137) were treated either with 125 micrograms ivsm cloprostenol or 500 micrograms i.m. cloprostenol (n = 28 vs 33, respectively) during peak breeding (September-February) or low breeding (March-August) season (n = 37 vs 39, respectively). Buffalo observed in estrus were inseminated twice with frozen-thawed semen at 12 and 22 h after the onset of estrus. Buffalo that failed to exhibit estrus were given a second equal dose of cloprostenol at an 11-d interval and underwent fixed-time insemination at 72 and 96 h. The interval to the onset of estrus was 85.0 +/- 4.4 vs 73.2 +/- 2.6 h during peak breeding and 96.1 +/- 2.6 vs 92.1 +/- 3.8 h during the low breeding season for buffalo treated with 125 and 500 micrograms cloprostenol, respectively. These intervals were different (P < 0.05) between seasons but not between treatments in the same season. Conception rates of 47.8 vs 53.1% during peak breeding and 23.5 vs 25.6% during low breeding season were also different (P < 0.05) between seasons but not between the treatments in the same season for buffalo treated with 125 and 500 micrograms cloprostenol, respectively. These results indicated that 125 micrograms ivsm and 500 micrograms i.m. cloprostenol were equally effective for synchronizing estrus in subestrous buffalo. No negative effect of a lower dose of cloprostenol was observed on estrus synchrony and subsequent fertility; however, season of treatment had a significant effect on conception rates.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10734427     DOI: 10.1016/s0093-691x(98)00211-8

Source DB:  PubMed          Journal:  Theriogenology        ISSN: 0093-691X            Impact factor:   2.740


  4 in total

1.  The ischiorectal fossa: an alternative route for the administration of prostaglandin in cattle.

Authors:  Marcos G Colazo; Marcelo F Martínez; John P Kastelic; Reuben J Mapletoft; Terry D Carruthers
Journal:  Can Vet J       Date:  2002-07       Impact factor: 1.008

2.  Alternative low doses and routes of administering a prostaglandin F2alpha analogue to induce luteolysis in Nelore cows.

Authors:  Cezinande Meira; Valsair Matos Pessoa; João Carlos Pinheiro Ferreira; Gustavo Henrique M Araujo; Marilu M Gioso; Sony Dimas Bicudo; Eunice Oba; Cassia Orlandi
Journal:  J Vet Sci       Date:  2006-12       Impact factor: 1.672

3.  A review of recent developments in buffalo reproduction - a review.

Authors:  H M Warriach; D M McGill; R D Bush; P C Wynn; K R Chohan
Journal:  Asian-Australas J Anim Sci       Date:  2015-03       Impact factor: 2.509

4.  Effects of treatment for anestrus in water buffaloes with PGF2α and GnRH in comparison with vitamin-mineral supplement, and some factors influencing treatment effects.

Authors:  Bhuminand Devkota; Toshihiko Nakao; Kosaku Kobayashi; Hiroshi Sato; Shyam Kishor Sah; Dinesh Kumar Singh; Ishwori Prasad Dhakal; Norio Yamagishi
Journal:  J Vet Med Sci       Date:  2013-07-24       Impact factor: 1.267

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.